Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma
Abstract
I read with great interest the article by Mitsue Saito and colleagues.1 The study reported that cadonilimab combined with chemotherapy achieved remarkably strong antitumor activity (objective response rate (ORR), 81.4% and disease control rate (DCR), 97.7%) in 43 enrolled participants and may represent a promising first-line treatment option for patients with advanced esophageal squamous cell carcinoma (ESCC). Although this single-arm phase II trial met its primary endpoint (ORR), several important issues warrant further clarification.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Esophageal Cancer Research and Treatment
Immune cells in cancer
Publication details
- Journal / source
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Volume
- 14
- Issue
- 1
- Pages
- e014391–e014391
- Publication date
- 1 January 2026
- Language
- EN